| 词条 | Lucitanib |
| 释义 |
| IUPAC_name = 6-({7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl}oxy)-N-methyl-1-naphthamide | image = Lucitanib.svg | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = By mouth | legal_AU = | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = Investigational | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = 31–40 hrs | duration_of_action = | excretion = | CAS_number = 1058137-23-7 | class = | ATCvet = | ATC_prefix = None | ATC_suffix = | PubChem = 25031915 | DrugBank = | ChemSpiderID = 28189586 | UNII = PP449XA4BH | KEGG = | ChEBI = 65209 | ChEMBL = 2180605 | synonyms = CO-3810, E-3810 | chemical_formula = | C=26 | H=25| N=3 | O=4 | smiles = CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC | StdInChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30) | StdInChIKey = CUDVHEFYRIWYQD-UHFFFAOYSA-N }}Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours[1] including metastatic breast cancer.[2] It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta.[1] References1. ^1 {{cite journal |pmid=25193991 |title=Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors |journal=Annals of Oncology |volume=25 |issue=11 |pages=2244–51 |doi=10.1093/annonc/mdu390 |last1=Soria |year=2014|url=http://annonc.oxfordjournals.org/content/25/11/2244.full}} {{antineoplastic-drug-stub}}2. ^{{ClinicalTrialsGov|NCT02053636|A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer (FINESSE)}} 2 : Receptor tyrosine kinase inhibitors|Carboxamides |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。